STI571 Prospective International RandomIsed Trial 2
A phase III, prospective randomised comparison of
-imatinib (STI571, Glivec/Gleevec) 400mg daily versus

• dasatinib (Sprycel) 100mg daily
  in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Closed to recruitment: March 2013
Last patient last visit : March 2018